SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Budson AE, Price BH. Memory dysfunction. N Engl J Med. 2005;352:692699.
  • 2
    Robbins TW, James M, Owen AM, et al. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge neuropsychological test automated battery. J Int Neuropsychol Soc. 1998;4:474490.
  • 3
    Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353361.
  • 4
    McClelland GR. The effects of practice on measures of performance. Hum Psychopharmacol. 1987;210:109118.
  • 5
    Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol. 2002;1:473.
  • 6
    Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002;17:179193.
  • 7
    Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008;70(19 Pt 2):18581866.
  • 8
    Thorndike EL, Lorge I. The Teacher's Word Book of 30,000 Words. New York: Columbia University; 1944.
  • 9
    Wesnes KA, Saxby B, Satek S, Ounpuu S, Ford G. Measurement of episodic memory using word tasks in Roman and non-Roman alphabet languages: validation from a multicentre clinical trial. Alzheimers Dement. 2009;5:457.
  • 10
    Galvin JE, Cornblatt B, Newhouse P, et al. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord. 2008;22:3038.
  • 11
    Vellas B, Cunha L, Gertz HJ, et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin. 2005;21:14231429.
  • 12
    Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13:183192.
  • 13
    Wesnes KA, McKeith IG, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:16541656.
  • 14
    Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77:11361142.
  • 15
    Wesnes KA. Assessing change in cognitive function in dementia: the relative utilities of the Alzheimer's disease assessment scale-cognitive subscale and the cognitive drug research system. Neurodegener Dis. 2008;5:261263.
  • 16
    Wesnes KA, Hildebrand K, Mohr E. Computerised cognitive assessment. In: WilcockGW, BucksRS, RockwoodK, eds. Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford: Oxford University Press; 1999:124136.
  • 17
    McGuinness B, Barrett SL, Craig D, Lawson J, Passmore AP. Attention deficits in Alzheimer's disease and vascular dementia. J Neurol Neurosurg Psychiatry. 2010;81:157159.
  • 18
    Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology. 2000;54:16161625.
  • 19
    Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59:17141720.
  • 20
    Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2:229237.
  • 21
    McKeith IG, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:1928.
  • 22
    Simpson PM, Surmon DJ, Wesnes KA, Wilcock G. The cognitive drug research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6:95102.
  • 23
    Nicholl CG, Lynch S, Kelly CA, et al. The Cognitive Drug Research computerised assessment system in the evaluation of early dementia – is speed of the essence? Int J Geriatric Psychiatry. 1995;10:199206.
  • 24
    Newhouse P, Levin E, White H, et al. Transdermal Nicotine Treatment of Mild Cognitive Impairment (MCI): A Multi-Center Pilot Study. Paper presented at American Association for Geriatric Psychiatry, March 2–4, 2009, Honolulu, Hawaii. 2009.
  • 25
    McGuinness B, Barrett SL, Craig D, et al. Executive functioning in Alzheimer's disease and vascular dementia. Int J Geriatric Psychiatry. 2010;25:518562.
  • 26
    Wilens TE, Klint T, Adler L, et al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct. 2008;4:24.
  • 27
    Wesnes KA, Edgar C, Dean ADP, Wroes SJ. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2009;14:522528.
  • 28
    Benton D, Nabb S, Ruffin MP, Lang V. The influence on memory of breakfasts differing in the content of rapidly and slowly available glucose. Appetite. 2003;40:317190.
  • 29
    Wesnes KA, Pincock C, Richardson D, Helm G, Hails S. Breakfast reduces declines in attention and memory over the morning in schoolchildren. Appetite. 2003;41:329331.
  • 30
    Scholey AB, Kennedy DO. Cognitive and physiological effects of an “energy drink”: an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. Psychopharmacology (Berl). 2004;176:320330.
  • 31
    Benton D, Griffiths R, Haller J. Thiamine supplementation mood and cognitive functioning. Psychopharmacology (Berl). 1997;129:6671.
  • 32
    Wesnes KA, Zangara A, Scholey A, Kennedy D. Natural products as cognition enhancing agents. In: BuccafuscoJJ, ed. Cognition Enhancing Drugs. Basel: Birkhauser Verlag; 2004:151178.
  • 33
    Collerton J, Collerton D, Arai Y, et al. A comparison of computerized and pencil-and-paper tasks in assessing cognitive function in community-dwelling older people in the Newcastle 85+ Pilot Study. J Am Geriatr Soc. 2007;55:16301635.